Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus R Herrlinger

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Digestive Diseases (Basel, Switzerland)|November 20, 2013
Differences between treatment guidelines--GermanyKlaus R Herrlinger
Visceral Medicine|June 1, 2017
Volume and Quality in Visceral MedicineKlaus R Herrlinger, Tobias Keck
The New England Journal of Medicine|September 10, 2010
Infliximab, azathioprine, or combination therapy for Crohn's diseaseKlaus R Herrlinger, Eduard F Stange
MMW Fortschritte Der Medizin|December 12, 2022
[JAK inhibitors - a new therapeutic option for inflammatory bowel disease]Klaus R Herrlinger, Eduard F Stange
Journal of Internal Medicine|June 15, 2021
Twenty-five years of biologicals in IBD: What´s all the hype about?Klaus R Herrlinger, Eduard F Stange
MMW Fortschritte Der Medizin|November 21, 2025
Eduard F Stange, Klaus R Herrlinger
Expert Review of Gastroenterology & Hepatology|July 22, 2023
Prioritization in inflammatory bowel disease therapyKlaus R Herrlinger, Eduard F Stange
Expert Review of Gastroenterology & Hepatology|December 22, 2023
To STRIDE or not to STRIDE: a critique of "treat to target" in Crohn´s diseaseKlaus R Herrlinger, Eduard F Stange
Journal of Crohn'S & Colitis|December 18, 2013
The debated role for thiopurines in Crohn's diseaseKlaus R Herrlinger, Eduard F Stange
Expert Review of Gastroenterology & Hepatology|August 28, 2024
To STRIDE or not to STRIDE: a critique of "treat to target" in ulcerative colitisKlaus R Herrlinger, Eduard F Stange
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Digestive Diseases (Basel, Switzerland)|November 20, 2013
Differences between treatment guidelines--GermanyKlaus R Herrlinger
Visceral Medicine|June 1, 2017
Volume and Quality in Visceral MedicineKlaus R Herrlinger, Tobias Keck
The New England Journal of Medicine|September 10, 2010
Infliximab, azathioprine, or combination therapy for Crohn's diseaseKlaus R Herrlinger, Eduard F Stange
MMW Fortschritte Der Medizin|December 12, 2022
[JAK inhibitors - a new therapeutic option for inflammatory bowel disease]Klaus R Herrlinger, Eduard F Stange
Journal of Internal Medicine|June 15, 2021
Twenty-five years of biologicals in IBD: What´s all the hype about?Klaus R Herrlinger, Eduard F Stange
MMW Fortschritte Der Medizin|November 21, 2025
Eduard F Stange, Klaus R Herrlinger
Expert Review of Gastroenterology & Hepatology|July 22, 2023
Prioritization in inflammatory bowel disease therapyKlaus R Herrlinger, Eduard F Stange
Expert Review of Gastroenterology & Hepatology|December 22, 2023
To STRIDE or not to STRIDE: a critique of "treat to target" in Crohn´s diseaseKlaus R Herrlinger, Eduard F Stange
Journal of Crohn'S & Colitis|December 18, 2013
The debated role for thiopurines in Crohn's diseaseKlaus R Herrlinger, Eduard F Stange
Expert Review of Gastroenterology & Hepatology|August 28, 2024
To STRIDE or not to STRIDE: a critique of "treat to target" in ulcerative colitisKlaus R Herrlinger, Eduard F Stange
Pageof 4